tradingkey.logo

Transmedics Group Inc

TMDX
127.670USD
+6.600+5.45%
收盤 12/19, 16:00美東報價延遲15分鐘
4.36B總市值
47.17本益比TTM

Transmedics Group Inc

127.670
+6.600+5.45%

關於 Transmedics Group Inc 公司

TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.

Transmedics Group Inc簡介

公司代碼TMDX
公司名稱Transmedics Group Inc
上市日期May 02, 2019
CEOHassanein (Waleed H)
員工數量728
證券類型Ordinary Share
年結日May 02
公司地址200 Minuteman Road
城市ANDOVER
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編01810
電話19785520900
網址https://www.transmedics.com/
公司代碼TMDX
上市日期May 02, 2019
CEOHassanein (Waleed H)

Transmedics Group Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Dr. Waleed H. Hassanein, M.D.
Dr. Waleed H. Hassanein, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
481.61K
-8.98%
Mr. James R. Tobin
Mr. James R. Tobin
Independent Chairman of the Board
Independent Chairman of the Board
177.21K
+1.22%
Dr. David Weill, M.D.
Dr. David Weill, M.D.
Independent Director
Independent Director
12.13K
--
Mr. Nicholas (Nick) Corcoran
Mr. Nicholas (Nick) Corcoran
Senior Vice President - Supply Chain and Operations
Senior Vice President - Supply Chain and Operations
7.04K
-44.49%
Ms. Merilee Raines, CPA
Ms. Merilee Raines, CPA
Independent Director
Independent Director
4.06K
+110.86%
Ms. Stephanie Lovell
Ms. Stephanie Lovell
Independent Director
Independent Director
4.06K
+110.86%
Mr. Thomas James Gunderson
Mr. Thomas James Gunderson
Independent Director
Independent Director
4.06K
+110.86%
Mr. Gerardo Hernandez
Mr. Gerardo Hernandez
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
331.00
-97.93%
Mr. Anil Ranganath
Mr. Anil Ranganath
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
--
--
Mr. Edwin M. Kania, Jr.
Mr. Edwin M. Kania, Jr.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Waleed H. Hassanein, M.D.
Dr. Waleed H. Hassanein, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
481.61K
-8.98%
Mr. James R. Tobin
Mr. James R. Tobin
Independent Chairman of the Board
Independent Chairman of the Board
177.21K
+1.22%
Dr. David Weill, M.D.
Dr. David Weill, M.D.
Independent Director
Independent Director
12.13K
--
Mr. Nicholas (Nick) Corcoran
Mr. Nicholas (Nick) Corcoran
Senior Vice President - Supply Chain and Operations
Senior Vice President - Supply Chain and Operations
7.04K
-44.49%
Ms. Merilee Raines, CPA
Ms. Merilee Raines, CPA
Independent Director
Independent Director
4.06K
+110.86%
Ms. Stephanie Lovell
Ms. Stephanie Lovell
Independent Director
Independent Director
4.06K
+110.86%

收入明細

單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
OCS Liver net revenue
116.11M
74.26%
OCS Heart net revenue
35.67M
22.81%
OCS Lung net revenue
4.58M
2.93%
地區USD
名稱
營收
佔比
United States
152.19M
97.34%
All other countries
4.16M
2.66%
業務
地區
業務USD
名稱
營收
佔比
OCS Liver net revenue
116.11M
74.26%
OCS Heart net revenue
35.67M
22.81%
OCS Lung net revenue
4.58M
2.93%

股東統計

更新時間: 11月25日 週二
更新時間: 11月25日 週二
持股股東
股東類型
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
13.86%
Fidelity Management & Research Company LLC
13.45%
The Vanguard Group, Inc.
10.53%
State Street Investment Management (US)
3.74%
Two Sigma Investments, LP
3.10%
其他
55.32%
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
13.86%
Fidelity Management & Research Company LLC
13.45%
The Vanguard Group, Inc.
10.53%
State Street Investment Management (US)
3.74%
Two Sigma Investments, LP
3.10%
其他
55.32%
股東類型
持股股東
佔比
Investment Advisor
71.86%
Investment Advisor/Hedge Fund
23.66%
Hedge Fund
7.08%
Research Firm
4.62%
Individual Investor
2.95%
Bank and Trust
2.15%
Pension Fund
1.35%
Sovereign Wealth Fund
0.18%
Insurance Company
0.10%

機構持股

更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
762
37.62M
110.09%
-8.17M
2025Q2
746
42.27M
124.01%
-2.30M
2025Q1
751
42.32M
125.08%
-2.32M
2024Q4
728
40.09M
119.11%
-642.74K
2024Q3
673
39.30M
117.10%
+1.37M
2024Q2
615
36.53M
110.85%
-3.27M
2024Q1
544
37.44M
113.97%
-4.28M
2023Q4
512
38.18M
116.94%
-3.46M
2023Q3
482
38.42M
117.77%
-240.92K
2023Q2
462
35.43M
108.88%
-81.81K
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
BlackRock Institutional Trust Company, N.A.
4.73M
13.87%
-97.24K
-2.02%
Jun 30, 2025
Fidelity Management & Research Company LLC
4.63M
13.57%
-32.85K
-0.71%
Jun 30, 2025
The Vanguard Group, Inc.
3.59M
10.53%
+21.12K
+0.59%
Jun 30, 2025
State Street Investment Management (US)
1.29M
3.78%
-17.52K
-1.34%
Jun 30, 2025
Two Sigma Investments, LP
692.64K
2.03%
+666.54K
+2554.00%
Jun 30, 2025
Nomura Investment Management Business Trust
952.11K
2.79%
-163.49K
-14.66%
Jun 30, 2025
Geode Capital Management, L.L.C.
804.65K
2.36%
+11.24K
+1.42%
Jun 30, 2025
Driehaus Capital Management, LLC
854.04K
2.51%
+75.28K
+9.67%
Jun 30, 2025
Hood River Capital Management LLC
679.85K
1.99%
-115.92K
-14.57%
Jun 30, 2025
Emerald Advisers LLC
694.97K
2.04%
-22.39K
-3.12%
Jun 30, 2025
查看更多

持股ETF

更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
Global X HealthTech ETF
4.75%
Clough Select Equity ETF
2.87%
Invesco S&P SmallCap Health Care ETF
2.75%
State Street SPDR S&P Health Care Equipment ETF
2.18%
Invesco S&P SmallCap 600 Pure Growth ETF
1.54%
First Trust Nasdaq Lux Digi Health Solutions ETF
1.47%
iShares S&P Small-Cap 600 Growth ETF
0.63%
State Street SPDR S&P 600 Small Cap Growth ETF
0.61%
First Trust Multi-Manager Small Cap Opportunities ETF
0.58%
Vanguard S&P Small-Cap 600 Growth Index Fund
0.58%
查看更多
Global X HealthTech ETF
佔比4.75%
Clough Select Equity ETF
佔比2.87%
Invesco S&P SmallCap Health Care ETF
佔比2.75%
State Street SPDR S&P Health Care Equipment ETF
佔比2.18%
Invesco S&P SmallCap 600 Pure Growth ETF
佔比1.54%
First Trust Nasdaq Lux Digi Health Solutions ETF
佔比1.47%
iShares S&P Small-Cap 600 Growth ETF
佔比0.63%
State Street SPDR S&P 600 Small Cap Growth ETF
佔比0.61%
First Trust Multi-Manager Small Cap Opportunities ETF
佔比0.58%
Vanguard S&P Small-Cap 600 Growth Index Fund
佔比0.58%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據

常見問題

Transmedics Group Inc的前五大股東是誰?

Transmedics Group Inc的前五大股東如下:
BlackRock Institutional Trust Company, N.A.
持有股份:4.73M
佔總股份比例:13.87%。
Fidelity Management & Research Company LLC
持有股份:4.63M
佔總股份比例:13.57%。
The Vanguard Group, Inc.
持有股份:3.59M
佔總股份比例:10.53%。
State Street Investment Management (US)
持有股份:1.29M
佔總股份比例:3.78%。
Two Sigma Investments, LP
持有股份:692.64K
佔總股份比例:2.03%。

Transmedics Group Inc的前三大股東類型是什麼?

Transmedics Group Inc 的前三大股東類型分別是:
BlackRock Institutional Trust Company, N.A.
Fidelity Management & Research Company LLC
The Vanguard Group, Inc.

有多少機構持有Transmedics Group Inc(TMDX)的股份?

截至2025Q3,共有762家機構持有Transmedics Group Inc的股份,合計持有的股份價值約為37.62M,占公司總股份的110.09% 。與2025Q2相比,機構持股有所增加,增幅為-13.93%。

哪個業務部門對Transmedics Group Inc的收入貢獻最大?

在FY2025Q2,OCS Liver net revenue業務部門對Transmedics Group Inc的收入貢獻最大,創收116.11M,占總收入的74.26% 。
KeyAI